CCR5 market seen reaching $2.48 billion by 2030

The global market for CC chemokine receptor type 5 is projected to grow from $1.54 billion in 2025 to $1.7 billion in 2026, according to The Business Research Company. The report points to rising chronic disease rates, more HIV cases and expanding immunology research as the main forces behind the forecast.

Why it matters: - CCR5 is a key target in HIV and immune-related drug development, so growth in this market signals more demand for targeted therapies. - The report ties future demand to broader disease burdens, including chronic illness and HIV, both of which keep pressure on treatment pipelines. - The market’s projected rise suggests continued investment in precision medicine and immune modulation.

What happened: - The Business Research Company published a report on the global CC chemokine receptor type 5 market. - The market is estimated at $1.54 billion in 2025 and is forecast to reach $1.7 billion in 2026. - The report projects the market will climb to $2.48 billion by 2030. - The forecast covers North America, Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - Download a free sample of the report. - View the full market report.

The details: - The 2025-2026 increase implies a 10.1% compound annual growth rate. - The report says historical growth has been driven by recognition of CCR5’s role in HIV infection, early CCR5 inhibitor development, immunology research programs, clinical trials for inflammatory diseases and targeted receptor therapies. - Future growth is linked to personalized immunotherapies, HIV treatment innovation, an expanding oncology drug pipeline, more investment in immune modulation research and targeted receptor drug design. - The report highlights CCR5 antagonist therapies, broader oncology use, precision drug development and stronger HIV and immunology research as key trends. - CCR5 is a protein on white blood cells that helps guide immune cells to inflammation or infection sites. - CCR5 also acts as a co-receptor that helps HIV enter immune cells. - Chronic disease prevalence is cited as a major driver, including heart disease, diabetes and arthritis. - CDC data from April 2025 showed about 194 million U.S. adults, or 76.4%, reported at least one chronic condition in 2023. - That CDC data included 59.5% of young adults, 78.4% of midlife adults and 93.0% of older adults. - HIV prevalence is another driver. - Minority HIV/AIDS Fund data cited in the report said about 39.9 million people worldwide were living with HIV in 2023, including 38.6 million adults and 1.4 million children.

Between the lines: - The forecast reflects how CCR5 sits at the intersection of infectious disease and chronic inflammation research. - A larger pipeline for oncology and immune-targeted drugs suggests CCR5 may continue to matter beyond HIV-focused therapies. - North America’s position as the largest regional market in 2025 points to strong research capacity and treatment demand in the region.

What's next: - The report expects continued market expansion through 2030 as drug developers pursue CCR5-based and immune-modulating therapies. - Regional opportunities will likely track disease burden, healthcare infrastructure and research spending. - The Business Research Company says its 2026 market reports include market attractiveness scoring, TAM analysis, company scoring matrices, forecasting dashboards and trend graphics.

The bottom line: - CCR5 is moving from a specialized HIV target to a broader platform for immune and oncology drug development, and the market outlook reflects that shift.